-
31.发明申请公开(公告)号：US20110027299A1
公开(公告)日：2011-02-03
申请号：US12851729
申请日：2010-08-06
摘要： The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.
摘要翻译： 本发明提供了包含gp100（SEQ ID NO：121）和相关核酸，表达载体，宿主细胞，细胞群和使用方法的8-15个连续氨基酸的分离或纯化的免疫原性肽。 本发明还提供衍生自gp100的免疫原性肽，其已被修饰以增强其免疫原性和相关核酸，表达载体，宿主细胞，细胞群和使用方法。
-
公开(公告)号：US07807805B2
公开(公告)日：2010-10-05
申请号：US11772277
申请日：2007-07-02
IPC分类号： C07H21/02
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
-
公开(公告)号：US07749719B2
公开(公告)日：2010-07-06
申请号：US11932406
申请日：2007-10-31
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
-
公开(公告)号：US20080292647A1
公开(公告)日：2008-11-27
申请号：US11932826
申请日：2007-10-31
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
-
35.发明申请公开(公告)号：US20080286804A1
公开(公告)日：2008-11-20
申请号：US11932406
申请日：2007-10-31
IPC分类号： G01N33/53
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
摘要翻译： 本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。 本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。 本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。 本发明还提供衍生自MART-1黑素瘤抗原或gp100抗原的免疫原性肽，其已被修饰以增强其免疫原性。 所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。
-
36.发明授权
公开(公告)号：US5994523A
公开(公告)日：1999-11-30
申请号：US7961
申请日：1998-01-16
IPC分类号： A01K67/027 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K14/82 , C07K16/32 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , G01N33/577 , C07H21/04 , C12N15/63
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
摘要翻译： 本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。 本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。 本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。 所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.046 秒)
